microdosing glp-1 agonists Microdosing, Brain Health & Alzheimer's Prevention GLP-1 Microdosing, Brain Health &
Description
Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.
Methods We conducted a population-based propensity-matched retrospective cohort study using TriNetX
The magnitude of the benefits of GLP-1RA and SGLT-2 inhibitors on MACE are similar, ranging from 12 to 14% reduction of risk, but only GLP-1RA may reduce the risk of stroke
Citing its post-market evaluation that found no increased risk of suicidal ideation or behavior, the U.S
The primary outcome was major adverse cardiovascular events (MACE)
